CSIMarket
 

Nascent Biotech Inc   (NBIO)

Nascent Biotech Inc 's

Competitiveness




 

NBIO Sales vs. its Competitors Q4 2024



Comparing the current results to its competitors, Nascent Biotech Inc reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.84 %, recorded in the same quarter.

List of NBIO Competitors





Revenue Growth Comparisons




Net Income Comparison


Nascent Biotech Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 30.04 %

<<  NBIO Stock Performance Comparisons


Nascent Biotech Inc 's Comment on Competition and Industry Peers


The company operates in a competitive environment focused on the development and commercialization of new cancer treatments. It faces competition from major pharmaceutical, biotechnology, and specialty cancer companies, including Ambit Biosciences, Array Biopharma, Genentech, Merk, Roche, and Takeda, which invest substantial resources in research and development. The company is in an early stage with no operational history and has acquired rights to its drug candidates. Competitors often possess greater financial resources, technical expertise, clinical development experience, and capabilities in manufacturing, regulatory affairs, and global commercialization. Additional competition arises from academic institutions, governmental agencies, and private organizations engaged in cancer research. The company seeks to protect its intellectual property through patents and trade secrets but recognizes that such protections may be incomplete or circumvented by competitors.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Nascent Biotech Inc




Sanofi
Share Performance



-11.86%
This Year



Sanofi
Profile

Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.

More about Sanofi's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 104,200.512 mill. $ 52,321.040 mill. $ 8,793.120 mill.


Biohaven Ltd
Share Performance



+9.43%
This Quarter



Biohaven Ltd
Profile

Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.

More about Biohaven Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,236.954 mill. $ - mill. $ -586.841 mill.


Legend Biotech Corporation
Share Performance



+5.49%
Over The Past 5 Days



Legend Biotech Corporation
Profile

Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.

More about Legend Biotech Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 6,871.472 mill. $ 1,751.341 mill. $ -296.800 mill.


Therapeuticsmd Inc
Share Performance



+4.85%
30 Days



Therapeuticsmd Inc
Profile

TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.

More about Therapeuticsmd Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 25.149 mill. $ 3.270 mill. $ -0.217 mill.


Eqrx Inc
Share Performance



0.00%
Over The Past 5 Days



Eqrx Inc
Profile

Eqrx Inc is a pharmaceutical company that focuses on creating affordable and accessible medication. They employ an innovative business model that combines research and development with scientific expertise to develop generic alternatives to the high-priced drugs in the market. By bypassing the traditional pharmaceutical pricing system, Eqrx aims to make essential medications more affordable for patients and healthcare providers.

More about Eqrx Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,133.098 mill. $ - mill. $ -259.623 mill.

120 more competitors available

Sign in to see all competitors

Sources: Nascent Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nascent Biotech Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.